Cholecystokinin-8 vs Cotadutide
Head-to-head comparison of Cholecystokinin-8 (Cholecystokinin (sulfated C-terminal octapeptide, CCK-8)) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cholecystokinin-8 | Cotadutide |
|---|---|---|
| Category | Endocrine Peptides | Weight Management |
| Full Name | Cholecystokinin (sulfated C-terminal octapeptide, CCK-8) | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | 1143.2 Da | ~4,700 Da |
| Half-Life | 1-2 min | Approximately 24 hours |
| Amino Acids | DY(SO3H)MGWMDF-NH2 | 37 |
| Typical Dose | physiologic low-picomolar-nanomolar range|research-dependent | 0.3-3 mg daily in clinical studies |
| Route | endogenous secretion|research IV/SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 97 | 18 |
| Research Status | Endogenous | Clinical |
Cholecystokinin-8 Benefits
- ✓gallbladder contraction
- ✓pancreatic enzyme release
- ✓satiety signaling
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Cholecystokinin-8 Dosing
physiologic secretion|research-dependent
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Cholecystokinin-8 Side Effects
- ⚠abdominal cramping
- ⚠nausea
- ⚠biliary contraction
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Cholecystokinin-8
CCK-8 is a canonical gut hormone fragment with extensive documentation in digestive physiology and appetite control. Sulfation of the tyrosine residue is important for high-affinity receptor activity.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.